Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.
Your search for bevacizumab returned 5 results
The approval was based on data from the phase 3 KEYNOTE-826 trial.
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
There was no improvement in overall survival with bevacizumab.
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.